Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (May 2022)
10 slides from Harrow's investor presentation, May 2022
Slide 1: Corporate Presentation | May 2022
Corporate Presentation | May 2022 1
Slide 2: Safe Harbor
Safe Harbor This presentation contains express “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying a
Slide 3: Harrow Health, Inc. (NASDAQ: HROW)
Harrow Health, Inc. (NASDAQ: HROW) ➢ U.S. ophthalmic-focused pharmaceutical company, providing both branded FDA-approved products (BPPs) and cGMP compounded products (CPPs) to more than 10,000 doctors, hospitals and ASCs. ➢ 43% year-over-year revenue growth rate (Q1 2022 vs. Q1 2021). ➢ 16% year-ove
Slide 4: Harrow's Ophthalmic Pharmaceuticals Business
Harrow’s Ophthalmic Pharmaceuticals Business ➢ A vertically integrated pharmaceutical and pharmacy platform, consisting of national sales and customer service teams, automated cGMP drug compounding facilities, and an efficient, scalable, and tech-enabled national distribution platform for prescripti
Slide 5: Revenues, Core Gross Margin and Assets
Revenues, Core Gross Margin and Assets (Revenues and Assets in Thousands) $98,329 $97,595 75% 76% 75% 70% 67% $72,476 60% 51% $59,085 $57,474 50% $56,252 46% $51,165 $49,451 $48,871 34% $41,372 $27,247 $26,774 Record $23,917 $22,120 $19,942 $14,131 $15,443 $10,242 $9,716 $1,660 2014 2015 2016 2017 2
Slide 6: Adjusted E(L)BITDA Growth and Expense Control
Adjusted E(L)BITDA Growth and Expense Control (Dollars in Thousands) $19,473 199% 130% $5,700 $4,600 $4,276 $4,940 95% $200 77% 73% 73% 70% 64% $(7,000) 57% $(10,000) $(10,000) 2015 2016 2017 2018 2019 2020 2021 1Q21 1Q22 Adjusted E(L)BITDA Operating Expense as a % of Revenue 6
Slide 7: Growth: High-Value FDA-Approved Products
Growth: High-Value FDA-Approved Products ➢ In 2021, we raised $85 million (sale of $10 million in Eton stock and $75 million in unsecured senior notes): ➢ AMP-100 in the U.S. and Canada; PDUFA target date of October 16, 2022 ➢ If approved, commercial focus will be ophthalmic procedures requiring the
Slide 8: Other Value: Equity Holdings and Royalty Pipeline
Other Value: Equity Holdings and Royalty Pipeline ➢ Surface Ophthalmics and Melt Pharmaceuticals were founded as Harrow Health subsidiaries. ➢ Surface was carved out in May 2018 and Melt was carved out in February 2019. ➢ Harrow owns: ➢ Equity in Surface and Melt (20% and 46%, respectively); ➢ $13.5
Slide 9: Summary of Harrow Health (NASDAQ: HROW)
Summary of Harrow Health (NASDAQ: HROW) ➢ 2022 expectations: Growing revenues, stable gross margins and OpEx/revenue ratio. ➢ Completed seven accretive/consequential deals during last 18 months; others in various stages of progress. ➢ Revenues expected to more than double within a few years of produ
Slide 10: Contact: 102 Woodmont Blvd., Nashville, Tennessee
102 Woodmont Blvd., Ste 610 Nashville, Tennessee 37205 www.HarrowInc.com Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com Direct: 615-733-4737 10